Johnson & Johnson announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012. Operational results increased 6.3% and the negative impact of currency was 1.8%. Domestic sales increased 7.4%, while international sales increased 2.4%, reflecting operational growth of 5.6% and a negative currency impact of 3.2%. Worldwide sales for the full-year 2013 were $71.3 billion, an increase of 6.1% versus 2012. Operational sales increased 7.7% and the negative impact of currency was 1.6%. Domestic sales increased 7%, while international sales increased 5.4%, reflecting operational growth of 8.2% and a negative currency impact of 2.8%.
“Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our pharmaceutical business, the strength of key brands in our U.S. OTC and other consumer businesses and continued progress in integrating Synthes into our medical devices and diagnostics business. We also advanced our longer-term growth drivers, bringing innovative solutions to the global health care market and executing with excellence,” said Alex Gorsky, J&J chairman and CEO. “I am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and consumers around the world.”
For its worldwide consumer division, which includes personal care and beauty brands such as Neutrogena, Clean & Clear and Lubriderm, recorded sales of $14.7 billion for the full-year 2013, representing an increase of 1.7% versus the prior year and consisting of an operational increase of 2.8% and a negative impact from currency of 1.1%. Domestic sales increased 2.3%; international sales increased 1.4%, which reflected an operational increase of 3.1% and a negative currency impact of 1.7%. Positive contributors to operational results included international sales of baby care products; sales of Neutrogena and Aveeno skin care products; and international sales of Listerine oral care products.
Learn more details of J&J’s Q4 2013 financial results, including information on its pharmaceutical business, here.